Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Since its founding in 2014, a16z Bio+ Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund ...

The market seems to share this optimistic view, since Eli Lilly and has a short interest of only 0.9% (this is the percentage ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

FacebookTweetPin Energy, healthcare, and chip stocks are carrying the market today. The S&P 500 Energy sector is up 2.16%, ...

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...